Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 9 - Medicinal preparations characterised by special physical form
Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
11/2003
11/27/2003WO2003097008A2 Transdermal delivery device for the administration of fentanyl
11/27/2003WO2003097007A2 Aqueous ophthalmic composition comprising a lyotropic mesomorphic lipid
11/27/2003WO2003096991A2 Amelioration of the development of cataracts and other opthalmic diseases
11/27/2003WO2003096976A2 Microcrystalline cewllulose compositions
11/27/2003WO2003096975A2 Pharmaceutical compositions and methods of using c-21 modified epothilone derivatives
11/27/2003WO2003096973A2 A direct cellular energy delivery system
11/27/2003WO2003096968A2 Oral osmotic controlled drug delivery system
11/27/2003WO2003096963A1 Powder compaction and enrobing
11/27/2003WO2003096944A1 Methods and formulations for the delivery of pharmacologically active agents
11/27/2003WO2003096874A2 Coated sustained release tablets of a hygroscopic compound for once-a-day therapy
11/27/2003WO2003080034A3 Method for the production and the use of microparticles and nanoparticles by constructive micronisation
11/27/2003WO2003070315A3 Temperature control system for cutaneous photodynamic therapy
11/27/2003WO2003061636A3 Dna dosage forms
11/27/2003WO2003053336A3 Methods for the treatment of peripheral neural and vascular ailments
11/27/2003WO2003051288A3 Mycobacterial vaccine
11/27/2003WO2003042344A3 Apo2 ligand/trail formulations
11/27/2003WO2003041651A3 Allatoin-containing skin cream
11/27/2003WO2003028656A3 Adjuvant compositions
11/27/2003WO2003028649A3 Novel composition of carvedilol
11/27/2003WO2003026594A3 Use of microcapsules containing ginger oil
11/27/2003WO2003020235A3 Stabilisation of oxidation-sensitive and uv-sensitive active ingredients
11/27/2003WO2003018038A3 Composition for the treatment of varicose veins
11/27/2003WO2003011208A3 Composition based on lipid lamellar vesicles incorporating at least a dhea compound
11/27/2003WO2003011207A3 Oral pharmaceutical composition comprising an active principle capable of being subjected to high effect during its first passage through the intestine
11/27/2003WO2003009817A3 Stable lyophilized pharmaceutical formulation of igg antibodies
11/27/2003WO2003007802A3 Pharmaceutical combinations of oxycodone and naloxone
11/27/2003WO2003004091A3 Aromatic sulfenates for type i phototherapy
11/27/2003WO2002094283A3 Use of phospholipids in the treatment of degenerative lung disease such as copd or cystic fibrosis and to enhance delivery of drugs
11/27/2003WO2002092147A3 Optimization of the molecular properties and formulation of proteins delivered by inhalation
11/27/2003WO2002089769A3 Method for applying an active ingredient to a substrate, compositions for said method, container containing a composition and use of said compositions
11/27/2003WO2002078830A3 Granulation method and device using focused acoustic energy
11/27/2003WO2002078604A3 Transdermal delivery of bioactive material
11/27/2003WO2002072095A3 Tiotropium salts for treating inflammatory diseases
11/27/2003WO2002070014A8 Compositions comprising an o/w emulsion containing conjugated linoleic acid
11/27/2003WO2002067903A3 Compositions and methods of manufacture for oral dissolvable dosage forms
11/27/2003WO2002060950B1 Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy
11/27/2003WO2002060385A3 Pharmaceutical formulation
11/27/2003WO2002056896A3 Treatment solution in addition to dressing material for caring for wounds
11/27/2003WO2001078727A8 Topical formulations for the transdermal delivery of niacin and methods of treating hyperlipidemia
11/27/2003WO2000050046A8 Stabilized oral pharmaceutical composition containing iodide and iodate and method
11/27/2003US20030220610 Device and method for delivering or withdrawing a substance through the skin
11/27/2003US20030220501 A chemical intermediates for making phthalimidoamlodipine, and further deprotecting to form amlodipine calcium channel blockers
11/27/2003US20030220483 Comprises fibroblast growth factor homologous factor- 1 (FHF-1) for disgnosing, prevention and treatment of neurodegenerative or neoplastic disorders
11/27/2003US20030220413 Coating and binding agent for oral or dermal pharmaceutical forms
11/27/2003US20030220403 Mixtures of 2-((diphenylmethyl) sulfinyl) acetamide, diluents, disintegrants, binders and lubricants, mixed to form solid dosages suitable for oral administration
11/27/2003US20030220391 Taxoids such as 3'-tert-butyl-3'-N-tert-butyloxycarbonyl-4-deacetyl-3'-dephenyl-3'-N -debenzoyl-4-O-methoxycarbonyl-paclitaxel, used as antitumor agents
11/27/2003US20030220382 Amines such as 2-((2-N,N-di-n-pentylamino)-indan-5-yl)amino-5 -nitro-benzoic acid, administered for prophylaxis of Alzheimer's disease
11/27/2003US20030220378 Oral administration of epothilones
11/27/2003US20030220351 Enteric coating made of methacrylic acid copolymer; system may also include a subcoating; resists disintegration and release of caffeine at pH less than 5, but disintegrates rapidly to release caffeine at pH greater than 6
11/27/2003US20030220336 Use of p38 kinase inhibitors for preparation of pharmaceutical composition suitable for inhalation therapy
11/27/2003US20030220312 Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of cardiovascular disorders
11/27/2003US20030220302 Combination of flunixin or the meglumine salt with a fluorinated chloramphenicol or thiamphenicol derivative antibiotic such as florfenicol
11/27/2003US20030220293 Having high dissolution profile and in vivo enhanced bioavailability
11/27/2003US20030220292 Treatment of erectile dysfunction
11/27/2003US20030220284 Adenoviral DNA comprises a circular form; and a therapeutic polynucleotide.
11/27/2003US20030220281 To inhibit the activity of elastase or cathepsin G, thereby inhibiting ectopic implantation of endometrial fragments.
11/27/2003US20030220270 Mono-and disaccharide derivatives
11/27/2003US20030220255 GLP-1 agonist and cardiovascular complications
11/27/2003US20030220254 Composition and method for preparation of an oral dual controlled release formulation of a protein and inhibitor
11/27/2003US20030220242 Aqueous prolonged release formulation
11/27/2003US20030220237 Pharmaceutical composition
11/27/2003US20030220226 Compounds and compositions for delivering active agents
11/27/2003US20030219909 Materials containing multiple layers of vesicles
11/27/2003US20030219514 Casing of a gelatin-free, water- based, set hydrocolloid gel that forms an enclosure, and at least one solid, liquid, soft or particulate center enclosed by the casing
11/27/2003US20030219500 Drink for athletes; creatine plays a pivotal role in the regulation and homeostasis of skeletal muscle energy metabolism
11/27/2003US20030219497 Methods of treating ileus
11/27/2003US20030219491 Compositions for inhibiting tumor growth and methods thereof
11/27/2003US20030219490 Nanoparticulate megestrol formulations
11/27/2003US20030219489 Solid pharmaceutical dispersions with enhanced bioavailability
11/27/2003US20030219488 Sustained-release formulation of a cyclooxygenase-2 inhibitor
11/27/2003US20030219485 A core containing a mixture of glipizide, a hydrophilic polymer and other excipients, a semipermeable wall surrounding the core(impermeable to content of core permeable to fluids) and a release passageways through the wall
11/27/2003US20030219484 A dosage form containing at least one active ingredient, which comprises a core and a shell with one or more openings, and readily soluble in gastrointestinal fluid, surrounding the core
11/27/2003US20030219483 Osmotic device containing venlafaxine and an anti-psychotic agent
11/27/2003US20030219482 Multiparticulate compositions for once-a-day administration
11/27/2003US20030219481 A controlled release dosage form for oral administration containing aglipizide or salt, a controlled release matrix cotaining gelling agent, an ionizable gel strength enhcancer and an inert diluent
11/27/2003US20030219480 Controlled release of drugs from a monolithic tablet for oral delivery containing granules of a drug, granulated with an amino acid, and an intragranular polymer, the granules are then dispersed within hydrophilic extragranular polymer
11/27/2003US20030219479 Including a mucoadhesive layer, containing a non-ionic polymer, a ionic polymer, a swelling modifier, a buffer; an effervescent layer containing a permeatin enhancer, an effervescent couple, and a binder; and an active agent
11/27/2003US20030219478 The filling of a pullulan based capsule including an aldehyde group in the molecule, or a precursor
11/27/2003US20030219477 Soft shell gelatin capsules containing non-steroidal anti-inflammatories
11/27/2003US20030219476 Administering to a mammal a pharmaceutical formulation containing mitoxantrone in a cardiolipin (a liposome), and a excipient to treat cancer and multiple sclerosis
11/27/2003US20030219475 Preservation of bioactive materials by freeze dried foam
11/27/2003US20030219474 A polynucleotide that hybridizes to a Bcl-2-encoding polynucleotide and a lipid associated with such polynuclotide
11/27/2003US20030219473 A lipid based cochelate formed of a purified soy- based phospholipid such as soy phosphatidylserine, and a multivalent cation selected from calcium, magnesium and zinc
11/27/2003US20030219472 Compositions and method for transmucosal drug delivery and cryoprotection
11/27/2003US20030219471 Administering to a menstruating female a cycle of contraceptive therapy, including, for at least 42 successive days, the administration of a combination of an estrogen and a progestogen as contraceptive daily dosage
11/27/2003US20030219470 Electrical apparatus for heating to a desired temperature for improved administration of pharmaceutically active compounds
11/27/2003US20030219465 Composition for delivery of dithranol
11/27/2003US20030219453 Vaccines
11/27/2003US20030219420 Methods for inducing the differentiation of monocytes into functional dendritic cells and immunotherapeutic compositions including such dendritic cells
11/27/2003US20030219405 Oral administration of interferon-tau
11/27/2003US20030219398 A copolymer comprising acryloyldimethyltauric acid and vinyl pyrrolidone and crosslinking monomer allyl acrylate or methacrylate monomers; oil emulsions or water in oil emulsions for cosmetic and drug use
11/27/2003US20030219392 Composition to enhance permeation of topical skin agents
11/27/2003US20030219388 Remineralizing dental adhesive film
11/27/2003US20030219384 Sustained release; polyelectrolyte shell encapsulating drug; crosslinked melamine-formaldehyde resin
11/27/2003US20030217908 Method and apparatus for transferring substrates
11/27/2003CA2752143A1 Delivery of nucleic acid-like compounds
11/27/2003CA2486801A1 Method of prophylaxis of infection
11/27/2003CA2486635A1 Drug delivery assembly
11/27/2003CA2486468A1 Improvements in delivery technology
11/27/2003CA2486461A1 Powder compaction and enrobing
1 ... 2061 2062 2063 2064 2065 2066 2067 2068 2069 2070 2071 2072 2073 2074 2075 2076 2077 2078 2079 2080 2081 ... 2991